Rising Skin Disease Prevalence to Drive Scar Treatment Market Growth

Advancing at a 10.5% CAGR, the scar treatment market is expected to garner revenue of $34.9 billion by 2023, witnessing a huge jump from the 2017 revenue which was $19.2 billion. The body’s natural response to injuries and broken skin leads to scar formation. Scars are made of fibrous tissue and may occur due to infections, injuries, surgeries, and inflammation of a tissue. Scar treatment is the employment of various methods to reduce the prominence of scars by using ointments, creams, and other treatment methods, such as lasers.

To Learn more about this report: http://bit.ly/2PENlpj

In recent times, silicon-based products have been trending in the scar treatment market. Such products, which have been found to be highly effective in reducing scars, are increasingly being recommended by doctors and cosmetic surgeons. These products have proven effective in reducing numerous types of scars, including keloid, acne, stretch marks, hypertrophic, and post-surgical. Some of the popular silicon-based scar reduction products available in the market are Avocet Polymer Technologies Inc.’s Avosil Scar Care Ointment, Perrigo Company PLC’s ScarAway, and Alliance Pharma PLC’s Kelo-Cote gel and spray.

Another factor driving the scar treatment market is the rising prevalence of skin diseases due to exposure to ultraviolet radiation and pollution. These have led to the increasing incidence of vitiligo, sunburn, atopic dermatitis, reduced skin elasticity, psoriasis, wrinkles, hyperpigmentation, and many other issues. These conditions, if not treated timely or properly, may result in scars. Among all these conditions, the most common cause of scar formation is acne. Nearly 85.0% of Americans in the age group of 12–24 suffer from at least minor acne, as reported by the American Academy of Dermatology.

Based on type of scar, the categories of the scar treatment market are stretch marks, post-surgical, contracture, acne, and keloid and hypertrophic scars. The largest revenue in 2017 was generated by the treatment of post-surgical scars. This can be attributed to the growing number of surgical procedures across the globe. The same factor is expected to support the post-surgical scar category in being the highest revenue generator during the forecast period (2018–2023).

Hence, as people become even more conscious of how they look and the prevalence of burns and chronic diseases rises further, so will the sales of scar treatment products.